［1］Chinese Society of Hematology，Chinese Medical Association/Chinese Society of Lymphoma，Chinese Anti-cancer Association.Chinese guidelines for diagnosis and treatment of difuse large B cell lymphoma（2013）［J］.Chin J Hematol，2013，34(9)：816-819.［中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会.中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)［J］.中华血液学杂志，2013，34(9)：816-819.］
[2]Jiang Wenqi，Huang Huiqiang.The evolution and curative effect of diffuse large B cell lymphoma treatment in China［J］.Chin J Hematol，2014，35(4)：357-360.［姜文奇，黄慧强.中国弥漫大B细胞淋巴瘤治疗方案的演变及疗效［J］.中华血液学杂志，2014，35(4)：357-360.］
[3]Izutsu K.Malignant lymphoma：Pathophysiology and current therapy［J］.Rinsho Ketsueki，2017，58(5)：480-486.
[4]Ito T，Ando H，Suzuki T，et al.Identification of a primary target of thalidomide teratogenicity［J］.Science，2010，327(5971)：1345-1350.
[5]A Lopez-Girona，D Mendy，T Ito，et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide［J］.Leukemia，2012，26(11)：2326-2335.
[6]Gandhi AK，Kang J，Havens CG，et al.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducingdegradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)［J］.Br J Haematol，2014，164(6)：811-821.
[7]Zhang LH，Kosek J，Wang M，et al.Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression［J］.Br J Haematol，2013，160(4)：487-502.
[8]Hernandez-Ilizaliturri FJ，Reddy N，Holkova B，et al.Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model［J］.Clin Cancer Res，2005，11(16)：5984-5992.
[9]Monti S，Savage KJ，Kutok JL，et al.Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including onecharacterized by host inflammatory response［J］.Blood，2005，105(5)：1851-1861.
[10]Caligiuri MA.Human natural killer cells［J］.Blood，2008，112(3)：461-469.
[11]Gribben JG，Fowler N，Morschhauser F.Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma［J］.J Clin Oncol，2015，33(25)：2803-2811.
[12]Zitvogel L，Kepp O，Kroemer G.Immune parameters affecting the efficacy of chemotherapeutic regimens［J］.Nat Rev Clin Oncol，2011，8(3)：151-160.
[13]Wu L，Adams M，Carter T，et al.Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells［J］.Clinical Cancer Research，2008，14(14)：4650-4657.
[14]Sakamaki I，Kwak LW，Cha SC，et al.Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas［J］.Leukemia，2014，28(2)：329-337.
[15]Nowakowski GS，LaPlant B，Macon WR，et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma：A phase II study［J］.J Clin Oncol，2015，33(3)：251-257.
[16]Nowakowski GS，LaPlant B，Habermann TM，et al.Lenalidomidecan be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas：Phase I study［J］.Leukemia，2011，25(12)：1877-1881.
[17]Thieblemont C，Tilly H，Gomes da Silva M，et al.Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone［J］.J Clin Oncol，2017，20：726-784.
[18]Nowakowski GS，Chiappella A，Witzig TE，et al.ROBUST：Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma［J］.Future Oncol，2016，12(13)：1553-1563.
[19]Habermann TM，Lossos IS，Justice G，et al.Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma［J］.Br J Haematol，2009，145(3)：344-349.
[20]Ferreri AJ，Sassone M，Zaja F，et al.Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation：An open label，single-arm，multicentre phase 2 trial［J］.Lancet Haematol，2017，4(3)：e137-e146.
[21]Hernandez-Ilizaliturri FJ，Deeb G，Zinzani PL，et al.Higher response tolenalidomide in relapsed/refractory diffuse large B-cell lymphomain nongerminal center B-cell-like than in germinal center B-cell-like phenotype［J］.Cancer，2011，117(22)：5058-5066.
[22]Mondello P，Steiner N，Willenbacher W，et al.Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma：Is it a valid treatment option［J］?Oncologist，2016，21(9)：1107-1112.
[23]Ivanov V，Coso D，Chetaille B，et al.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma［J］.Leuk Lymphoma，2014，55(11)：2508-2513.
[24]Wang M，Fowler N，Wagner-Bartak N，et al.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell，follicular and transformed lymphoma：A phase II clinical trial［J］.Leukemia，2013，27(9)：1902-1909.
[25]Tilly H，Morschhauser F，Salles G，et al.Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma［J］.Leukemia，2013，27(1)：252-255.
[26]Vitolo U，Chiappella A，Franceschetti S，et al.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma：Results of the REAL07 open-label，multicentre，phase 2 trial［J］.Lancet Oncol，2014，15(7)：730-737.
[27]Martín A，Redondo AM，Dlouhy I，et al.Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma：A phase 1b study from GELTAMO group［J］.Br J Haematol，2016，173(2)：245-252.
[28]Feldman T，Mato AR，Chow KF，et al.Addition of lenalidomide to rituximab，ifosfamide，carboplatin，etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma［J］.Br J Haematol，2014，166(1)：77-83.
[29]Zinzani PL，Pellegrini C，Derenzini E，et al.Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients［J］.Hematol Oncol，2013，31(4)：223-224.